208 related articles for article (PubMed ID: 27853642)
21. NK-cell Editing Mediates Epithelial-to-Mesenchymal Transition via Phenotypic and Proteomic Changes in Melanoma Cell Lines.
Huergo-Zapico L; Parodi M; Cantoni C; Lavarello C; Fernández-Martínez JL; Petretto A; DeAndrés-Galiana EJ; Balsamo M; López-Soto A; Pietra G; Bugatti M; Munari E; Marconi M; Mingari MC; Vermi W; Moretta L; González S; Vitale M
Cancer Res; 2018 Jul; 78(14):3913-3925. PubMed ID: 29752261
[TBL] [Abstract][Full Text] [Related]
22. Delivery of 5'-triphosphate RNA with endosomolytic nanoparticles potently activates RIG-I to improve cancer immunotherapy.
Jacobson ME; Wang-Bishop L; Becker KW; Wilson JT
Biomater Sci; 2019 Jan; 7(2):547-559. PubMed ID: 30379158
[TBL] [Abstract][Full Text] [Related]
23. Targeting intrinsic RIG-I signaling turns melanoma cells into type I interferon-releasing cellular antitumor vaccines.
Bek S; Stritzke F; Wintges A; Nedelko T; Böhmer DFR; Fischer JC; Haas T; Poeck H; Heidegger S
Oncoimmunology; 2019; 8(4):e1570779. PubMed ID: 30906666
[TBL] [Abstract][Full Text] [Related]
24. Melanoma suppression by quercein is correlated with RIG-I and type I interferon signaling.
Peng D; Chen L; Sun Y; Sun L; Yin Q; Deng S; Niu L; Lou F; Wang Z; Xu Z; Wang C; Fan L; Wang H; Wang H
Biomed Pharmacother; 2020 May; 125():109984. PubMed ID: 32066042
[TBL] [Abstract][Full Text] [Related]
25. Expression, crystallization and X-ray diffraction analysis of a complex between B7-H6, a tumor cell ligand for the natural cytotoxicity receptor NKp30, and an inhibitory antibody.
Xu X; Li Y; Gauthier L; Chen Q; Vivier E; Mariuzza RA
Acta Crystallogr F Struct Biol Commun; 2015 Jun; 71(Pt 6):697-701. PubMed ID: 26057798
[TBL] [Abstract][Full Text] [Related]
26. Evidence that the cellular ligand for the human NK cell activation receptor NKp30 is not a heparan sulfate glycosaminoglycan.
Warren HS; Jones AL; Freeman C; Bettadapura J; Parish CR
J Immunol; 2005 Jul; 175(1):207-12. PubMed ID: 15972650
[TBL] [Abstract][Full Text] [Related]
27. Endothelial RIG-I activation impairs endothelial function.
Asdonk T; Motz I; Werner N; Coch C; Barchet W; Hartmann G; Nickenig G; Zimmer S
Biochem Biophys Res Commun; 2012 Mar; 420(1):66-71. PubMed ID: 22402283
[TBL] [Abstract][Full Text] [Related]
28. Melanoma Affects the Composition of Blood Cell-Derived Extracellular Vesicles.
Koliha N; Heider U; Ozimkowski T; Wiemann M; Bosio A; Wild S
Front Immunol; 2016; 7():282. PubMed ID: 27507971
[TBL] [Abstract][Full Text] [Related]
29. RIG-I immunotherapy overcomes radioresistance in p53-positive malignant melanoma.
Lambing S; Tan YP; Vasileiadou P; Holdenrieder S; Müller P; Hagen C; Garbe S; Behrendt R; Schlee M; van den Boorn JG; Bartok E; Renn M; Hartmann G
J Mol Cell Biol; 2023 Jun; 15(1):. PubMed ID: 36626927
[TBL] [Abstract][Full Text] [Related]
30. Exosomes Derived From Natural Killer Cells Exert Therapeutic Effect in Melanoma.
Zhu L; Kalimuthu S; Gangadaran P; Oh JM; Lee HW; Baek SH; Jeong SY; Lee SW; Lee J; Ahn BC
Theranostics; 2017; 7(10):2732-2745. PubMed ID: 28819459
[No Abstract] [Full Text] [Related]
31. Therapeutic efficacy of bifunctional siRNA combining TGF-β1 silencing with RIG-I activation in pancreatic cancer.
Ellermeier J; Wei J; Duewell P; Hoves S; Stieg MR; Adunka T; Noerenberg D; Anders HJ; Mayr D; Poeck H; Hartmann G; Endres S; Schnurr M
Cancer Res; 2013 Mar; 73(6):1709-20. PubMed ID: 23338611
[TBL] [Abstract][Full Text] [Related]
32. Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells.
Castriconi R; Cantoni C; Della Chiesa M; Vitale M; Marcenaro E; Conte R; Biassoni R; Bottino C; Moretta L; Moretta A
Proc Natl Acad Sci U S A; 2003 Apr; 100(7):4120-5. PubMed ID: 12646700
[TBL] [Abstract][Full Text] [Related]
33. 5'-Triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma.
Poeck H; Besch R; Maihoefer C; Renn M; Tormo D; Morskaya SS; Kirschnek S; Gaffal E; Landsberg J; Hellmuth J; Schmidt A; Anz D; Bscheider M; Schwerd T; Berking C; Bourquin C; Kalinke U; Kremmer E; Kato H; Akira S; Meyers R; Häcker G; Neuenhahn M; Busch D; Ruland J; Rothenfusser S; Prinz M; Hornung V; Endres S; Tüting T; Hartmann G
Nat Med; 2008 Nov; 14(11):1256-63. PubMed ID: 18978796
[TBL] [Abstract][Full Text] [Related]
34. A Bifunctional Approach of Immunostimulation and uPAR Inhibition Shows Potent Antitumor Activity in Melanoma.
Matheis F; Heppt MV; Graf SA; Düwell P; Kammerbauer C; Aigner A; Besch R; Berking C
J Invest Dermatol; 2016 Dec; 136(12):2475-2484. PubMed ID: 27498344
[TBL] [Abstract][Full Text] [Related]
35. Important role for NKp30 in synapse formation and activation of NK cells.
Wang H; Zheng X; Wei H; Tian Z; Sun R
Immunol Invest; 2012; 41(4):367-81. PubMed ID: 22221078
[TBL] [Abstract][Full Text] [Related]
36. RIG-I inhibits the MAPK-dependent proliferation of BRAF mutant melanoma cells via MKP-1.
Szabo A; Fekete T; Koncz G; Kumar BV; Pazmandi K; Foldvari Z; Hegedus B; Garay T; Bacsi A; Rajnavolgyi E; Lanyi A
Cell Signal; 2016 May; 28(5):335-347. PubMed ID: 26829212
[TBL] [Abstract][Full Text] [Related]
37. Mimicking an induced self phenotype by coating lymphomas with the NKp30 ligand B7-H6 promotes NK cell cytotoxicity.
Kellner C; Maurer T; Hallack D; Repp R; van de Winkel JG; Parren PW; Valerius T; Humpe A; Gramatzki M; Peipp M
J Immunol; 2012 Nov; 189(10):5037-46. PubMed ID: 23066150
[TBL] [Abstract][Full Text] [Related]
38. NK cell-mediated lysis of autologous antigen-presenting cells is triggered by the engagement of the phosphatidylinositol 3-kinase upon ligation of the natural cytotoxicity receptors NKp30 and NKp46.
Spaggiari GM; Carosio R; Pende D; Marcenaro S; Rivera P; Zocchi MR; Moretta L; Poggi A
Eur J Immunol; 2001 Jun; 31(6):1656-65. PubMed ID: 11385609
[TBL] [Abstract][Full Text] [Related]
39. Cyclophosphamide enhances the release of tumor exosomes that elicit a specific immune response in vivo in a murine T-cell lymphoma.
Cocozza F; Menay F; Tsacalian R; Elisei A; Sampedro P; Soria I; Waldner C; Gravisaco MJ; Mongini C
Vaccine; 2019 Mar; 37(12):1565-1576. PubMed ID: 30777349
[TBL] [Abstract][Full Text] [Related]
40. Therapeutically Active RIG-I Agonist Induces Immunogenic Tumor Cell Killing in Breast Cancers.
Elion DL; Jacobson ME; Hicks DJ; Rahman B; Sanchez V; Gonzales-Ericsson PI; Fedorova O; Pyle AM; Wilson JT; Cook RS
Cancer Res; 2018 Nov; 78(21):6183-6195. PubMed ID: 30224377
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
